Bruker integrates NGS into microbiology for enhanced infection diagnostics

AUSTRIA—Bruker’s Microbiology and Infection Diagnostics division has announced an expansion of its microbiology solutions into Next-Generation Sequencing (NGS) applications.

This initiative aims to enhance epidemiological studies and improve tracing of hospital-acquired infections (HAIs).

The announcement was made during the ESCMID Global 2025 conference, where Bruker also revealed a strategic partnership with Ridom GmbH, a bioinformatics company based in Münster, Germany.

Central to this collaboration is Ridom’s NGS software, SeqSphere+™, which provides tools for genomic differentiation of bacterial strains, multilocus sequence typing (MLST), core genome MLST (cgMLST), phylogenetic analysis, and real-time detection of clonal and plasmid transmission.

 The software is compatible with various NGS platforms, increasing its versatility.

The collaboration offers new workflows that combine rapid first-line testing with Bruker’s IR Biotyper® for cost-effective detection and exclusion of HAI outbreaks.

Following initial testing, selective NGS reflex testing can be performed for in-depth phylogenetic analysis.

Additionally, species identification using Bruker’s MALDI Biotyper® can be enhanced by sequencing key samples to gain deeper genomic insights.

These solutions are intended for research purposes and aim to address critical needs in hospital hygiene and epidemiological analysis.

Professor Dag Harmsen, founder and Managing Director of Ridom GmbH, expressed enthusiasm about joining Bruker’s global microbiology team.

 He praised Bruker’s long history of innovation in microbiology and emphasized that this collaboration will provide sustainable services for NGS customers while creating growth opportunities.

Professor John Rossen from the University of Groningen also commended the synergy between rapid microbial identification and genomic analysis, highlighting its potential to provide valuable insights into the spread of antibiotic resistance.

Dr. Wolfgang Pusch, President of Bruker’s Microbiology & Infection Diagnostics Division, emphasized the importance of these advancements.

He stated that combining IR Biotyper® and SeqSphere+™ represents a unique triage solution for healthcare settings by integrating rapid testing with detailed genomic interpretation.

While Ridom is reported to be profitable, the financial details of the investment were not disclosed.

This strategic move aligns with Bruker’s ongoing commitment to innovation in microbiology and positions the company to meet the growing demands in infectious disease diagnostics.